BioSpace News Archive

Alzheon, Inc. announced that it will be presenting at the 4th International Trisomy 21 Research Society Conference to be held on June 9-12, 2022 in Long Beach, California, USA.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced its participation in Credit Suisse’s Asia Healthcare Corporate Day, June 14-16, 2022.

ViewRay, Inc. announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy Center in Japan.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board (SAB) comprised of renowned leaders in neurology and neurodegenerative disease research.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlying causes and no approved treatment.

ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has initiated a research collaboration with Dr Shawn Kwatra, as an advisor, from Johns Hopkins University School of Medicine and Dr Madan Kwatra from Duke University Medical Center to investigate the unique role of the IL-13Ra1 subunit.

Demonstrates first-ever commercial product capable of single-cell RNA sequencing on FFPE tissues.

Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board.

REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jennifer Zachary to its Board of Directors, effective June 3, 2022.

Wilmington, Delaware, United States: Generic drugs are refereed to medications with same chemical makeup to that of existing branded drugs.